Mantle cell lymphoma, response to treatment and prognosis in 45 patients

Marc Sorigue, Juan Manuel Sancho, Olga García, Jordi Vila, Miriam Moreno, Josep Maria Ribera

Research output: Contribution to journalArticleResearchpeer-review


© 2016 Elsevier España, S.L.U. Background and purpose Mantle cell lymphoma (MCL) is a rare lymphoproliferative disorder, with frequent relapses and a poor prognosis. This study analyzes response to treatment and prognosis in a series of MCL patients. Patients and method Retrospective study of MCL patients diagnosed in a single institution between 1996 and 2013. The cohort was divided according to the treatment received. Results Forty-five patients were included (32 male) with a median age of 66 years old. Twenty-one received intensive chemotherapy or chemoimmunotherapy (based on high-dose cytarabine), 13 semi-intensive (without high-dose cytarabine), 8 not intensive and 3 did not require treatment. Overall response rate was 85% in the intensive and 77% in the semi-intensive treatment groups. In multivariate analysis, intensive treatment was correlated with a longer progression-free survival (hazard ratio 9.8 [95% CI 2.7-35.5], P = .001) and overall survival (4.5 [1.2-17.8], P = .03). Conclusions In this retrospective series of MCL patients, intensive treatment was correlated with better outcomes than the other treatment modalities.
Original languageEnglish
Pages (from-to)18-21
JournalMedicina Clinica
Issue number1
Publication statusPublished - 1 Jul 2016


  • High-dose cytarabine
  • Mantle cell lymphoma
  • Prognosis


Dive into the research topics of 'Mantle cell lymphoma, response to treatment and prognosis in 45 patients'. Together they form a unique fingerprint.

Cite this